Table 1.
Characteristics of the Study Population at Baseline, Stratified According to All‐Cause Mortality
| Overall Population (N=1551) | Survivors (n=1441) | Deceased (n=110) | P Value | |
|---|---|---|---|---|
| Age, y | 59.4±12.7 | 58.9±12.6 | 66.2±13.3 | <0.001 |
| Male sex | 527 (34) | 479 (33) | 48 (44) | 0.026 |
| NYHA functional class II or higher | 715 (46) | 643 (45) | 72 (66) | <0.001 |
| Syncopea | 357 (23) | 330 (23) | 27 (25) | 0.193 |
| Diabetes mellitus | 156 (10) | 148 (10) | 8 (7) | 0.314 |
| Arterial hypertension | 535 (34) | 502 (35) | 33 (30) | 0.304 |
| Chronic kidney disease | 115 (7) | 100 (7) | 15 (14) | 0.010 |
| NT‐proBNP, pg/mL) | 167 (68/472) | 149 (63/397) | 1133 (413/3213) | <0.001 |
| Abnormal NT‐proBNPb | 214 (14) | 158 (11) | 56 (51) | <0.001 |
| Medications | ||||
| Benznidazole treatmentc | 368 (26) | 357 (25) | 11 (10) | 0.001 |
| Loop diuretics | 327 (21) | 274 (19) | 53 (48) | <0.001 |
| ACEIs | 475 (31) | 447 (31) | 28 (26) | 0.258 |
| Angiotensin receptor blockers | 452 (29) | 403 (28) | 49 (45) | <0.001 |
| Spironolactone | 284 (18) | 245 (17) | 39 (36) | <0.001 |
| β‐Blockers (carvedilol) | 339 (22) | 288 (20) | 51 (46) | <0.001 |
| Digoxin | 132 (9) | 115 (8) | 17 (16) | 0.006 |
| Amiodarone | 386 (25) | 338 (23) | 48 (44) | 0.001 |
| ECG findings | ||||
| Heart rate, beats/min | 66±14.1 | 66±13.5 | 70±17.9 | 0.028 |
| Atrial fibrillation | 80 (5) | 66 (5) | 14 (13) | <0.001 |
| QTc interval, ms | 446.7±30.3 | 446.0±30.2 | 458.8±29.8 | <0.001 |
| QRS duration, ms | 120.4±29.0 | 119.3±28.3 | 136.3±34.7 | <0.001 |
| Pacemaker | 64 (4) | 48 (3) | 16 (15) | <0.001 |
| Isolated RBBB | 379 (24) | 358 (25) | 21 (19) | 0.167 |
| RBBB plus LAFB | 215 (14) | 196 (14) | 19 (17) | 0.283 |
| LBBB | 74 (5) | 60 (4) | 14 (13) | <0.001 |
| Ventricular ectopic beats | 52 (3) | 45 (3) | 7 (6) | 0.071 |
| Low QRS voltage | 109 (7) | 95 (6.6) | 14 (13) | 0.015 |
Data are expressed as mean±SD, median (interquartile range), or absolute numbers (percentage). ACEI indicates angiotensin‐converting enzyme inhibitor; LAFB, left anterior fascicular block; LBBB, left bundle‐branch block; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; RBBB, right bundle‐branch block.
a
Reported by the patients.
b
Considering age‐related cutoff values.
c
Previous treatment with benznidazole was not informed by 124 patients (8%).